Cargando…

Pharmacokinetics (PK) and Safety of Intravenous (IV) Brincidofovir (BCV) in Healthy Adult Subjects

BACKGROUND: BCV is a lipid conjugate nucleotide that has shown rapid viral clearance in patients with adenovirus infection and improved survival in animal models of smallpox. In preclinical studies in rats, IV BCV dosed twice weekly for up to 29 days was not associated with gastrointestinal (GI), he...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wire, Mary Beth, Morrison, Marion, Anderson, Maggie, Arumugham, Thangam, Dunn, John, Naderer, Odin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631843/ http://dx.doi.org/10.1093/ofid/ofx163.725

Ejemplares similares

1421. IV Brincidofovir (BCV): Pharmacokinetics (PK) and Safety of Multiple Ascending Doses (MAD) in Healthy Subjects
por: Naderer, Odin, et al.
Publicado: (2018)

Experimental reproduction of winter dysentery in lactating cows using BCV — comparison with BCV infection in milk-fed calves
por: Tråvén, M, et al.
Publicado: (2001)

1099. Evaluation of the Safety and Pharmacokinetics (PK) following Administration of Single and Multiple Doses of Anti-Staphylococcal Lysin, LSVT-1701, in Healthy Adult Subjects
por: Wire, Mary Beth, et al.
Publicado: (2021)

Safety, Tolerability, and Pharmacokinetics (PK) of Posaconazole (POS) Intravenous (IV) Solution and Oral Powder for Suspension in Children With Neutropenia
por: Groll, Andreas H, et al.
Publicado: (2017)

Experimental Treatment of Ebola Virus Disease with Brincidofovir
por: Dunning, Jake, et al.
Publicado: (2016)

1387. Phase I Study to Evaluate the Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Doses (SAD/MAD) of Intravenous (IV) Minocycline in Healthy Adult Subjects
por: Cornely, Oliver A, et al.
Publicado: (2018)

Base-Calling Algorithm with Vocabulary (BCV) Method for Analyzing Population Sequencing Chromatograms
por: Fantin, Yuri S., et al.
Publicado: (2013)

Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model
por: Hutson, Christina L., et al.
Publicado: (2021)

The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak
por: Foster, Scott A., et al.
Publicado: (2017)

722. Pharmacokinetics (PK) and Safety of Lefamulin (LEF) After Single Intravenous Dose Administration in Subjects With Impaired Hepatic Function
por: Wicha, Wolfgang, et al.
Publicado: (2019)

Pharmacokinetics (PK) of Eravacycline in Subjects with Renal or Hepatic Impairment Compared with Healthy Subjects
por: Horn, Patrick, et al.
Publicado: (2017)

Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies
por: Tippin, Timothy K., et al.
Publicado: (2016)

Rapid Virologic Response to Brincidofovir in Children with Disseminated Adenovirus Infection
por: Chan, Shuk Ying, et al.
Publicado: (2021)

Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug–drug interaction study
por: Tompson, Debra J, et al.
Publicado: (2014)

Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats
por: Fernández-Varón, Emilio, et al.
Publicado: (2016)

Correction for Hutson et al., “Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model”
por: Hutson, Christina L., et al.
Publicado: (2021)

705. Pharmacokinetics (PK) and Safety of Lefamulin (LEF) After Single Intravenous Dose Administration in Subjects With Impaired Renal Function and in Those Requiring Hemodialysis
por: Wicha, Wolfgang, et al.
Publicado: (2019)

Brincidofovir (CMX001) for the Treatment of Severe Adenoviral Pneumonia in Kidney Transplant Recipient
por: Sudhindra, Praveen, et al.
Publicado: (2019)

The Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GSK1322322 in Healthy Volunteers
por: Naderer, Odin, et al.
Publicado: (2015)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

Comparison of bovine coronavirus (BCV) antigens: Monoclonal antibodies to the spike glycoprotein distinguish between vaccine and wild-type strains
por: Hussain, Khalid A., et al.
Publicado: (1991)

Genomic relationship between turkey and bovine enteric coronaviruses identified by hybridization with BCV or TCV specific cDNA probes
por: Verbeek, A., et al.
Publicado: (1991)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation
por: Marty, Francisco M., et al.
Publicado: (2018)

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
por: Venisse, Nicolas, et al.
Publicado: (2020)

Successful Treatment of Adenovirus Infection with Brincidofovir in an Immunocompromised Patient after Hematological Stem Cell Transplantation
por: Van Genechten, T., et al.
Publicado: (2020)

Brincidofovir is a robust replication inhibitor against African swine fever virus in vivo and in vitro
por: Guo, Shibang, et al.
Publicado: (2023)

Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19
por: Lasky, Joseph A., et al.
Publicado: (2020)

Brincidofovir Use after Foscarnet Crystal Nephropathy in a Kidney Transplant Recipient with Multiresistant Cytomegalovirus Infection
por: Vial, Romain, et al.
Publicado: (2017)

1719. Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial
por: Bradley, John, et al.
Publicado: (2018)

New Acaciin-Loaded Self-Assembled Nanofibers as M(Pro) Inhibitors Against BCV as a Surrogate Model for SARS-CoV-2
por: Mohamad, Soad A, et al.
Publicado: (2021)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis
por: Lanier, E. Randall, et al.
Publicado: (2016)

Sensitivity of Human Mastadenovirus, the Causal Agent of Pharyngoconjunctival Fever, Epidemic Keratoconjunctivitis, and Hemorrhagic Cystitis in Immunocompromised Individuals, to Brincidofovir
por: Hanaoka, Nozomu, et al.
Publicado: (2022)

Pharmacokinetics, Metabolism, and Excretion of Intravenous [14C]Difelikefalin in Healthy Subjects and Subjects on Hemodialysis
por: Stark, Jeffrey G., et al.
Publicado: (2023)

PK-DB: pharmacokinetics database for individualized and stratified computational modeling
por: Grzegorzewski, Jan, et al.
Publicado: (2020)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

Oral Brincidofovir Therapy for Monkeypox Outbreak: A Focused Review on the Therapeutic Potential, Clinical Studies, Patent Literature, and Prospects
por: Imran, Mohd., et al.
Publicado: (2023)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_b2aubncpseaonicv46bl6mb0nr